Cargando…

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Savale, Laurent, Guignabert, Christophe, Weatherald, Jason, Humbert, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488842/
https://www.ncbi.nlm.nih.gov/pubmed/29653948
http://dx.doi.org/10.1183/16000617.0004-2018
_version_ 1784792750437171200
author Savale, Laurent
Guignabert, Christophe
Weatherald, Jason
Humbert, Marc
author_facet Savale, Laurent
Guignabert, Christophe
Weatherald, Jason
Humbert, Marc
author_sort Savale, Laurent
collection PubMed
description Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of therapeutic agents that modulate abnormalities in three major pathobiological pathways for PAH has revolutionised our approach to the treatment of PAH, the long-term survival rate remains unsatisfactory. Accumulating evidence has underlined that clinical outcomes and responses to therapy in PAH are modified by multiple factors, including genetic variations, which will be different for each individual. Since precision medicine, also known as stratified medicine or personalised medicine, aims to better target intervention to the individual while maximising benefit and minimising harm, it has significant potential advantages. This article aims to assemble and discuss the different initiatives that are currently underway in the PH/PAH fields together with the opportunities and prospects for their use in the near future.
format Online
Article
Text
id pubmed-9488842
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94888422022-11-14 Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era Savale, Laurent Guignabert, Christophe Weatherald, Jason Humbert, Marc Eur Respir Rev Series Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of therapeutic agents that modulate abnormalities in three major pathobiological pathways for PAH has revolutionised our approach to the treatment of PAH, the long-term survival rate remains unsatisfactory. Accumulating evidence has underlined that clinical outcomes and responses to therapy in PAH are modified by multiple factors, including genetic variations, which will be different for each individual. Since precision medicine, also known as stratified medicine or personalised medicine, aims to better target intervention to the individual while maximising benefit and minimising harm, it has significant potential advantages. This article aims to assemble and discuss the different initiatives that are currently underway in the PH/PAH fields together with the opportunities and prospects for their use in the near future. European Respiratory Society 2018-04-13 /pmc/articles/PMC9488842/ /pubmed/29653948 http://dx.doi.org/10.1183/16000617.0004-2018 Text en Copyright ©ERS 2018. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Series
Savale, Laurent
Guignabert, Christophe
Weatherald, Jason
Humbert, Marc
Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
title Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
title_full Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
title_fullStr Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
title_full_unstemmed Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
title_short Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
title_sort precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
topic Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488842/
https://www.ncbi.nlm.nih.gov/pubmed/29653948
http://dx.doi.org/10.1183/16000617.0004-2018
work_keys_str_mv AT savalelaurent precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera
AT guignabertchristophe precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera
AT weatheraldjason precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera
AT humbertmarc precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera